The Competence Centre for Cancer Research (CCCR) was founded in 2004 under the name of IBCC Holding Ltd. with the aim to save lives and reduce human suffering by developing and implementing new diagnostic platforms and offering the pharmaceutical industry new drug candidates.
Later the name of the company was changed to Competence Centre for Cancer Research. In 2016 CCCR became a member of an international group of pharmaceutical and healthcare companies, theBravo Group.
"A strong competence centre, gathering all major national players in a joint R&D effort with a high private co-funding indicating strong sustainability" – RegioStars Jury 2011
The ambition of the CCCR is to establish a strong long-term private-public partnership in top-level cancer research, based on the common vision of SME entrepreneurs and scientists. It includes improving economic value added and, in particular, supporting the access of biotechnology SMEs to hospitals and global markets.
The main innovation stems from the interdisciplinary partnerships involving chemists, molecular biologists, cell biologists, biochemists, immunologists, clinical doctors, radiologists, plant physiologists, economists, biotechnology business developers, clinical trials specialists, health care specialists etc. It enables CCCR to find innovative solutions to problems related to the early diagnosis and effective treatment of cancer.
The impact on the economy is evident in terms of expertise, new jobs, attractiveness for scientists and new services developed. These outcomes are largely due to a change of paradigm by fostering trust, support and sharing in a highly competitive area such as biomedicine. The CCCR consortium, involving all major players in cancer research in Estonia, has achieved significant results, notably it has out-licensed and/or transferred intellectual property developed under the CCCR framework to global companies; (i.e. oncogenetic tests used in top-level Estonian hospitals). New expertise has been developed that was missing in Estonia; new start-ups in biotechnology and in certain high-tech services needed for the CCCR projects with more graduate students specialised in applied cancer research. The entrepreneurs and scientists of the CCCR team have visited a similar competence centre in Sweden (Vinnova Programme). On the other hand the CCCR approach is an interesting example of interregional partnerships and the transfer of know-how. A Latvian team has visited the CCCR to start a similar project.
CCCR has been collaborating in different research and development projects with the following partners:
Tallinn University of Technology
North Estonia Medical Centre
Trial Form Support TFS AB
CeMines Estonia Ltd
Cambrex Tallinn Ltd
University of Helsinki
University of Tartu
Quattromed HTI Laborid Ltd
Competence Centres’ Programme
Estonian Ministry of Education and Science
Estonian Science Foundation
The research and development work of CCCR has been strongly supported by European Union via different programs. A number of novel solutions are in use in medical care or commercialised for further development.
In 2016 CCCR became a member of an international group of pharmaceutical and healthcare companies, the Bravo Group. Currently CCCR is making the novel results of the research and development available worldwide. Our focus in new developments is on new predictive, preventive, personalised and participatory health care solutions.
CCCR has a daughter company, Catherine's Biomedicals Sweden AB in Sweden. The Strategic Aim of Catherine’s Biomedicals Sweden is to collaborate with Swedish universities, hospitals, R&D institutions and innovative companies for joint development of cancer research projects, to enable an access of Swedish-developed and Swedish-made innovative solutions to the target markets of Bravo Group both in EU and outside EU, to support Swedish medical system with novel solutions in therapy and diagnostics.
CCR carries out its R&D projects together with partners from Finland, Germany, France, Sweden, Norway and the UK.